Akari Therapeutics Plc (AKTX): Price and Financial Metrics


Akari Therapeutics Plc (AKTX): $1.35

0.04 (+3.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 496

in industry

AKTX Stock Price Chart Interactive Chart >

Price chart for AKTX

AKTX Price/Volume Stats

Current price $1.35 52-week high $4.21
Prev. close $1.31 52-week low $1.29
Day low $1.29 Volume 70,100
Day high $1.40 Avg. volume 90,184
50-day MA $1.50 Dividend yield N/A
200-day MA $1.70 Market Cap 70.08M

Akari Therapeutics Plc (AKTX) Company Bio


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company is based in London, United Kingdom.


AKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

AKTX Latest Social Stream


Loading social stream, please wait...

View Full AKTX Social Stream

Latest AKTX News From Around the Web

Below are the latest news stories about Akari Therapeutics Plc that investors may wish to consider to help them evaluate AKTX as an investment opportunity.

Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced further development of a program for the inhaled delivery of nomacopan to the lung, working with Inhalation Sciences AB to refine dosing and pharmacokinetics of nomacopan for both dry powder

Yahoo | January 26, 2022

Akari says FDA agrees to use of new manufacturing process for nomacopan for trials

Akari Therapeutics (AKTX +0.2%) said the U.S. Food and Drug Administration (FDA) agreed to the clinical use of nomacopan derived from a next generation manufacturing process. Nomacopan, which is Akari’s lead drug candidate, is currently being evaluated in four areas: a rare skin condition called bullous pemphigoid; Thrombotic microangiopathy, a type of...

Seeking Alpha | January 19, 2022

FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercializationNEW YORK and LONDON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. F

Yahoo | January 19, 2022

Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present a Company overview at the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. The pre-recorded presen

Yahoo | January 4, 2022

Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s

Yahoo | December 30, 2021

Read More 'AKTX' Stories Here

AKTX Price Returns

1-mo -2.17%
3-mo -18.67%
6-mo -17.68%
1-year -46.64%
3-year -32.50%
5-year N/A
YTD -10.00%
2021 -18.92%
2020 5.71%
2019 11.46%
2018 -63.74%
2017 -38.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8062 seconds.